7 assets in Precursor T-Cell Acute Lymphoblastic Leukemia

Therapeutic assets addressing Precursor T-Cell Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) Precursor T-Cell Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Cytarabine Precursor T-Cell Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Venetoclax Precursor T-Cell Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
cd5-targeted car-t cells Precursor T-Cell Acute Lymphoblastic Leukemia	Peking University People's Hospital	P1/2	CCC (48)
Beam-201 Precursor T-Cell Acute Lymphoblastic Leukemia	Stephan Grupp MD PhD	P1	CC (43)
cd5 car t Precursor T-Cell Acute Lymphoblastic Leukemia	Beijing Boren Hospital	P1	CC (43)
Senl-T7 Precursor T-Cell Acute Lymphoblastic Leukemia	Hebei Senlang Biotechnology Inc., Ltd.	N/A	D (30)